obesity-congress-diabetes-congress-2018-tracks

8 / 18

Page 28
Note:
O c t o b e r 1 5 - 1 6 , 2 0 1 8 | T o k y o , J a p a n
Obesity Congress 2018, Diabetes Congress 2018 & Vaccines Congress 2018 Biomedical Research | ISSN: 0976-1683| Volume 29
2nd WORLD OBESITY CONGRESS
2nd WORLD VACCINES AND IMMUNOLOGY CONGRESS
&
&
DIABETES AND ENDOCRINOLOGY
International Conference on
Joint Event on
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
YEARS
Tirasak Pasharawipas, Biomed Res 2018, Volume 29 | DOI: 10.4066/biomedicalresearch-C5-013
THE ACCESS TO PRODUCE COMPATIBLE
VIRAL VACCINES FOR INDIVIDUALITY
Tirasak Pasharawipas
Rangsit University, Thailand
There is a question why viral vaccines cannot be effective for everybody.
This is a question that we need to revise our knowledge and manipulate
in the right direction for the viral vaccine production. To prevent a viral infec-
tion, a body must produce a protective antibody to prevent the viral particle
to attach the viral receptor on a target cell. Theoretically, adaptive immunity
needs induction not only by an antigen but also our cellular molecule called
major histocompatibility complex (MHC) to form a complex molecule with
its appropriate epitope to activate a specific receptor of T cell. There are two
classes of MHC molecules called class I and class II. MHC class I is required
for inducing cytotoxic T cell while MHC class II is for helper T cell. Helper T
cell plays a key role to induce an effective stage of acquired immunity includ-
ing a specific protective antibody. To produce the viral-specific antibody, MHC
class II plays a key role to induce helper T cell and then B cell to synthesize
a specific antibody. Since the MHC gene alleles are highly polymorphic so
the possibility that individuals have the same gene alleles might be one in
a million which, mostly, can be found in those who are an identical twin. Ac-
cordingly, a subunit viral vaccine, which contains a limit number of epitopes,
would reduce a capacity of an antigen presenting cell, such as a dendritic cell,
to process some epitopes to induce the helper T cell clones. Subsequently, in
some people, the corresponding B cell clones cannot synthesize the specific
antibody to neutralize the infectious viral particle. Accordingly, this presenta-
tion will present the novel approach to develop the viral vaccine for everybody.
Tirasak Pasharawipas has completed his PhD from Fac-
ulty of Microbiology, Mahidol University, Bangkok, Thai-
land. He has his postdoctoral training at NeuroVirology
and Cancer Biology Center, Temple University, Philadel-
phia. At present, he is a full Professor in Microbiology and
Immunology, Rangsit University, Thailand. His scientific
fields mainly focus in viral and cellular interaction, bac-
teriophage and viral diseases in invertebrate animals.
However, his research interests expand to viral vaccines,
autoimmune disease and cancer biology including the re-
lationship of MHC molecules to some specific diseases
and viral vaccines. He enjoys being a reviewer for several
journals and an advisor to develop young medical scien-
tists with the wish that they would co-operate and suc-
ceed to solve all the problematic diseases, now and then,
in a proper way with genuine scientific thinking.
BIOGRAPHY